浙江我武生物科技股份有限公司 第一条 为规范浙江我武生物科技股份有限公司（以下简称"公司"）信息披露行为， 加强信息披露事务管理，促进公司依法规范运作，维护公司和投资者的合法 权益，依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会《上市公 司信息披露管理办法》（以下简称"《管理办法》"）、《深圳证券交易所创业板 股票上市规则》（以下简称"《上市规则》"）、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》（以下简称"《规范运作》"） 等法律、法规和规范性文件及《浙江我武生物科技股份有限公司章程》（以下 简称"《公司章程》"）的有关要求，特制定本制度。 第二条 本制度所称信息披露是指达到证券监管部门和深圳证券交易所关于上市公司 信息披露的标准要求，根据相关法律、法规、部门规章及证券监管部门的规 范性文件，将可能对公司证券及衍生品种价格产生较大影响而投资者尚未得 知的重大信息，在规定时间内，通过规定的媒体，以规定的方式向社会公众 公布。 第三条 本制度所称"信息披露义务人"是指公司及其董事、高级管理人员、 ...

浙江我武生物科技股份有限公司 股东会议事规则 （2025 年 8 月） 第一章 总 则 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事 应当勤勉尽责，确保股东会正常召开和依法行使职权。 临时股东会不定期召开，有下列情形之一的，公司在 2 个月内召开临时 股东会： 1 第一条 为维护浙江我武生物科技股份有限公司（以下简称"公司"）及公司股 东的合法权益，明确股东会的职责权限，提高股东会议事效率，保证股 东会依法行使职权，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司 股东会规则》、《浙江我武生物科技股份有限公司章程》（以下简称"《公 司章程》"）以及其他的有关法律、法规规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关规定 召开股东会，保证股东能够依法行使权利。 第四条 股东会是公司的权力机构，应当在《公司法》和《公司章程》规定的范 围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开 1 次，应当 于 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-031 号 浙江我武生物科技股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 此次续聘会计师事务所事项符合财政部、国务院国资委、证监会印发的《国 有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 浙江我武生物科技股份有限公司（以下简称"公司"）于2025年8月21日召 开第五届董事会第十三次会议、第五届监事会第十次会议，审议通过了《关于续 聘容诚会计师事务所（特殊普通合伙）为公司2025年度审计机构的议案》，拟续 聘容诚会计师事务所（特殊普通合伙）（以下简称"容诚会计师事务所"）为公 司2025年度财务和内部控制审计机构。本事项尚需提交公司股东会审议通过，现 将有关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息。 截至 2024 年 12 月 31 日，容诚会计师事务所共有合伙人 196 人，共有注册 会计师 1549 人，其中 781 人签署过证券服务业务审计报告。 容诚会计师事务所经 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-032 号 浙江我武生物科技股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据 2024 年 7 月 1 日起正式施行的《中华人民共和国公司法》（2023 年修订）（以 下简称"新《公司法》"）、中国证券监督管理委员会（以下简称"中国证监会"）发布的 《关于新<公司法>配套制度规则实施相关过渡期安排》与《上市公司章程指引》（2025 年修订）、《深圳证券交易所创业板股票上市规则》（2025 年修订）、《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》（2025 年修订）等现行相关 法律、法规及规范性文件的规定，结合浙江我武生物科技股份有限公司（以下简称"公 司"）的实际情况，公司于 2025 年 8 月 21 日召开了第五届董事会第十三次会议、第五 届监事会第十次会议，审议通过了《关于修订<公司章程>的议案》。上述议案尚需经公 司股东会以特别决议审议通过后生效。现将有关情况公告如下： 一、由审计委员会行使监事会职权 本次《公司章 ...

月非经营性资金占用及其他关联资金往来情况 1-6 t 武生物科技股份有限公司 202 | | | | | | g | | | | 脚 | Hi 16 = 位 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占 | 资金占用 方名称 | 用方与上市公 司的关联关 | 上市公司核算 的会计科目 | 用资金余额 2025 年期初占 | 月占用 025 年 1-6 月占用 戈生金额以不含利 | 年 1-6 月利息 如有 025 | 2025 年 1-6 月偿 累计发生 | 用资金 2025年6月 | 用形成 ਸਿਟੀ 道 41 ELL | 用性 न | | 实际控制 空股股东、 | - | = | - | ー | | | | | - | H 性占 柳 非经 | | 及其附属企业 | 1 | . | = | - | | | . | 1 | - | ד 투 抑 非经 | | 小计 | . | . | - | - | . | . | = | . | . | - | | 前控股股东、实际控制 | . | = | - | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第十三次 会议决议，公司定于 2025 年 9 月 12 日（星期五）下午 14:30 召开公司 2025 年第一次临 时股东会。本次股东会将采取现场投票和网络投票相结合的方式，现将股东会的有关事 项通知如下： 一、召开会议的基本情况 1. 股东会届次：2025 年第一次临时股东会 证券代码：300357 证券简称：我武生物 公告编号：2025-033 号 浙江我武生物科技股份有限公司 关于召开 2025 年第一次临时股东会的通知 2. 会议召集人：浙江我武生物科技股份有限公司董事会 3. 会议召开的合法、合规性 公司第五届董事会第十三次会议审议通过《关于召开公司 2025 年第一次临时股东 会的议案》。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件、深圳 证券交易所业务规则和《公司章程》的相关规定。 4. 会议召开时间： （1）现场会议召开时间：2025 年 9 月 12 日（星期五）下午 14:30 （2）网络投票时间：2025 年 ...

第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届监事会第十次会议通 知于 2025 年 8 月 11 日以邮件方式发出。会议于 2025 年 8 月 21 日在公司上海分公司会 议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会议应出席监事 3 人，实 际出席监事 3 人。会议由监事会主席金桃女士召集并主持，公司董事会秘书列席了会议。 本次会议的召集、召开符合《中华人民共和国公司法》等有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 经与会监事认真审议，通过如下议案： 1. 审议通过《公司 2025 年半年度报告及其摘要》 证券代码：300357 证券简称：我武生物 公告编号：2025-028 号 浙江我武生物科技股份有限公司 具体内容详见公司在深圳证券交易所网站和符合中国证监会规定条件的媒体上同 日披露的《关于续聘会计师事务所的公告》。 表决结果：赞成：3 票；反对：0 票；弃权：0 票 本 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-027 号 浙江我武生物科技股份有限公司 1. 审议通过《公司 2025 年半年度报告及其摘要》 《公司 2025 年半年度报告》及《公司 2025 年半年度报告摘要》的编制和审核程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案报告中的财务信息已经审计委员会审议通过。 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第十三次会议 通知于 2025 年 8 月 11 日以邮件方式发出。会议于 2025 年 8 月 21 日在公司上海分公司 会议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会议应出席董事 6 人， 实际出席董事 6 人。会议由董事长胡赓熙先生召集并主持，公司部分监事、高级管理人 员列席了会议。本次会议的召集、召开符合《中华人民共和国公司法》等有关法律、 ...

Financial Performance - The company's operating revenue for the current reporting period is ¥484,236,510.36, representing a 12.81% increase compared to ¥429,257,047.81 in the same period last year[28]. - Net profit attributable to shareholders of the listed company is ¥177,008,721.63, an increase of 18.61% from ¥149,230,994.02 in the previous year[28]. - The net cash flow from operating activities is ¥200,515,852.10, showing a significant increase of 96.08% compared to ¥102,261,817.01 in the same period last year[28]. - Basic earnings per share are ¥0.3381, up 18.63% from ¥0.2850 in the previous year[28]. - Total assets at the end of the reporting period are ¥2,790,077,042.44, a 2.99% increase from ¥2,709,124,934.20 at the end of the previous year[28]. - The net assets attributable to shareholders of the listed company are ¥2,467,880,978.57, reflecting a 4.85% increase from ¥2,353,706,702.01 at the end of the previous year[28]. - The company achieved operating revenue of ¥484,236,510.36, a year-on-year increase of 12.81%[55]. - The net profit attributable to shareholders was ¥177,008,721.63, reflecting an 18.61% increase compared to the previous year[55]. - Sales revenue from dust mite drops reached ¥454,655,215.07, up 10.51% year-on-year[55]. - Sales revenue from mugwort pollen sublingual drops was ¥21,020,536.26, showing a significant growth of 71.37%[55]. - Sales revenue from skin prick solution increased by 104.38% to ¥6,327,765.88[55]. Product Development and Innovation - The company plans to enhance the promotion of new products such as "Artemisia Flower Pollen Sublingual Drops" and "Artemisia Flower Pollen Skin Prick Liquid" to mitigate risks associated with product concentration[11]. - The company emphasizes the importance of rigorous project initiation processes to accelerate the development of new drugs and minimize associated risks[12]. - The company is focusing on the development of natural drugs to combat antibiotic resistance, addressing a critical public health challenge due to the rise of multi-drug resistant bacteria[43]. - The company has a strong commitment to research and innovation in the field of natural drugs, leveraging China's rich biological resources and traditional medicine practices[43]. - The company is actively expanding into the stem cell field, supported by recent regulatory improvements and a significant market potential, with various policies promoting the development of the stem cell industry[41]. - The company is focusing on R&D investments in its core business while also expanding into other technological fields[90]. - The company has received approval for the clinical trial of "Dermatitis Diagnostic Patch 02," expanding its product pipeline in allergy diagnostics[91]. - The company aims to meet the allergen detection needs of various allergic disease patients through its expanded product offerings[141]. - The company is focused on developing new products in the allergy diagnosis field to address diverse patient needs[141]. Regulatory Environment and Compliance - The pharmaceutical industry faces increasing regulatory scrutiny, which may impact operational models and competitive dynamics[5]. - The company is committed to complying with industry regulations and will actively monitor policy changes to manage operational risks[7]. - New drug development is subject to lengthy regulatory processes, which could delay market entry and affect competitiveness[12]. - The regulatory environment for the biopharmaceutical industry in China is becoming more stringent, which may impact the research, production, and sales processes of pharmaceutical companies[39]. - The company is committed to compliance and risk management strategies to mitigate the impact of price reductions in drug tenders[82]. - The company has implemented a governance framework to enhance operational efficiency and risk management[93]. - The company emphasizes compliance with information disclosure regulations to ensure transparency and fairness for all investors[95]. Market Position and Strategy - The company maintains a leading position in the sublingual desensitization treatment market, with only its "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" approved for nationwide sale in China[40]. - The company reported a significant focus on enhancing existing product promotion to ensure sustainable growth despite external challenges[9]. - The company is exploring alternative sales channels to stabilize prices in response to bidding price reductions and other cost-control measures[8]. - The company’s competitive capabilities in the allergen product sector remain strong, with no significant changes in its market position[40]. - The company’s sublingual desensitization therapy has been increasingly recognized by clinical practitioners, with guidelines recommending it as a first-line treatment for allergic rhinitis and asthma[39]. - The company has established a robust quality control system, with a dedicated quality department overseeing the entire production process[54]. - The company’s marketing strategy focuses on regions with higher prevalence of allergic diseases, leveraging the seasonal nature of its products[53]. Financial Management and Investments - Research and development investment amounted to ¥61,682,073.51, accounting for 12.74% of total revenue, indicating a continued focus on innovation[61]. - The company has a total of 13 valid Chinese invention patents and 7 foreign invention patents, reflecting its strong commitment to intellectual property and innovation[61]. - The company has received an A rating for information disclosure from the Shenzhen Stock Exchange for three consecutive years[95]. - The company has distributed over ¥900 million in cash dividends since its listing, exceeding four times the initial fundraising amount[92]. - The company aims to maintain a profit distribution policy where cash dividends are greater than 30% of the net profit attributable to shareholders each year[92]. - The company has established a supplier evaluation team and management measures to maintain long-term stable relationships with quality suppliers[109]. Social Responsibility and Sustainability - The company is committed to sustainable development and social responsibility, aligning its strategies with the interests of employees and society[102]. - The company has initiated a patient assistance project to provide sublingual desensitization medication to children and adults suffering from allergic rhinitis, with a donation agreement signed with the Beijing Kangmeng Charity Foundation[113]. - The project aims to improve medication efficacy and adherence for patients with allergic rhinitis caused by mugwort pollen, reducing their economic burden[114]. - The company has committed to a green office initiative, promoting paperless operations to enhance environmental awareness among employees[111]. - The company has not experienced any major pollution incidents or environmental violations since its establishment, and all environmental protection facilities are operating normally[111]. Legal and Governance Issues - The company is involved in a lawsuit with Shanghai Lihui Equity Investment Partnership, with a disputed amount of CNY 14.18 million (approximately USD 2.1 million), which is currently under trial[121]. - The company has ongoing small claims litigation involving CNY 0.83 million (approximately USD 0.12 million), which is still in progress[121]. - There were no related party transactions during the reporting period, including asset or equity acquisitions[124][125]. - The company did not engage in any violations regarding external guarantees during the reporting period[118]. - The semi-annual financial report has not been audited[119]. - The company has not undergone any bankruptcy reorganization during the reporting period[120].

Core Viewpoint - The company is expected to achieve a net profit of 170 million to 185 million yuan in the first half of 2025, reflecting a year-on-year growth of 13.92% to 23.97%, maintaining its leading position in the field of allergic disease treatment [1] Group 1: Product Performance - The core product "Dust Mite Drops" continues to show strong growth, with sales revenue reaching 455 million yuan, a year-on-year increase of 10.51% [2] - The sales revenue of "Artemisia Pollen Allergen Sublingual Drops" is 21 million yuan, growing by 71.37% year-on-year, while "Skin Prick Test Solution" sales reached 6.3 million yuan, up 104.38% year-on-year, driven by increased market promotion efforts [2] Group 2: Innovation and R&D - The company is increasing its investment in innovative R&D, with multiple projects making significant progress, including the expansion of its allergen product pipeline [3] - New products such as "Sycamore Pollen Allergen Skin Prick Solution" and "German Cockroach Allergen Skin Prick Solution" have received approval for market application, enhancing the product pipeline [3] Group 3: Industry Environment - The incidence of allergic diseases is rising in China, driven by increased health awareness and environmental changes, leading to growing medical demand and technological advancements in the field [4] - The "Healthy China 2030" strategy emphasizes the prevention and treatment of allergic diseases, with desensitization therapy recognized as a key method, promoting clinical application and market expansion of related products [4] Group 4: Operational Quality - The company has optimized production processes and strengthened cost control, maintaining a high level of profitability and improving operational cash flow, indicating good financial health [5] - The company plans to continue focusing on the allergic disease field and accelerate the launch of in-development products, with expectations for sustained growth in performance [5] Group 5: Overall Performance Outlook - The company's performance in the first half of 2025 aligns with market expectations, showcasing resilience and a promising future driven by core product growth and innovation strategies [6]